arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Charles River Laboratories International, Inc.

CRL Health Care Biotechnology: Commercial Physical & Biological Resarch
$339.66
▲ +7.7% Today
as of Oct 22, 16:47 ET
Last 30 days +24.37% Sep 14 → Oct 22
$267.12 $288.00 $308.88 $329.75 $350.63 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$341.43
High
$351.21
Low
$337.78
Volume
$3M
Avg Vol
$943,677
Mkt Cap
$14.3B
P/E (TTM)
389.81
Beta
—
52w High
$351.21
52w Low
$146.20
Div Yield
—
Shares Out
$48M

Recent Press Releases & News last 60 days · 25 items

Oct 22 · 20:30 PR PR Newswire
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Oct 22 · 20:30 PR Business Wire
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Oct 22 · 14:11 Simply Wall St.
Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger
▸ Show all 25 press releases & news Free account →

CRL earnings at a glance

Charles River Laboratories International, Inc. (CRL) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of $2.97, compared with $2.43 in the same quarter last year (+22%). The options market is pricing a move of about ±5.5% after the report, a range of roughly $321.08 to $358.24 from today's $339.66. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±7.7% on average; after the most recent report on Aug 5, 2026 it moved +11.4%. That means options currently expect less movement than CRL has typically delivered. CRL beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 46%. The share price of $339.66 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$146
$351
94% of range
Avg surprise (last 6)
+10.3%
Avg reaction (last 6)
+2.3%
33% positive
Latest IV / EM
46%
EM ±5.5% · $300 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$1.30$1.76$2.21$2.67$3.12 Actual $2.01Actual $1.89Actual $1.69Actual $1.30Actual $1.74Actual $1.33Actual $2.34Est $2.06Actual $3.12Est $2.50Actual $2.43Est $2.32Actual $2.39Est $2.33Actual $2.06Est $1.96Actual $3.02Est $2.72 AprJulSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-15M$260M$534M$809M$1.1B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 5, 2026Jun/2026 $3.02 $2.72 +11.0% -12.8% +11.4% earnings
Thu May 7, 2026Mar/2026 $2.06 $1.96 +5.1% -12.0% -0.0% earnings
Wed Feb 18, 20268K 2026-02-18 $2.39 $2.33 +2.6% — -0.3% earnings
Wed Nov 5, 2025Sep/2025 $2.43 $2.32 +4.7% — -5.7% earnings
Wed Aug 6, 2025Jun/2025 $3.12 $2.50 +24.8% — -10.2% earnings
Wed May 7, 2025Mar/2025 $2.34 $2.06 +13.6% — +18.7% earnings
Sat Sep 28, 2024Sep 2024 $1.33 — — — — financials
Sat Jun 29, 2024Jun 2024 $1.74 — — — — financials
Sat Mar 30, 2024Mar 2024 $1.30 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.69 — — — — financials
Sat Jul 1, 2023Jul 2023 $1.89 — — — — financials
Sat Apr 1, 2023Apr 2023 $2.01 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER $2.97$2.43 +22.2%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1.00B$996M—$1.00B$1.03B$984M—$1.01B
Cost of revenue———————$661M
Gross profit————————
Operating income$120M$120M—$134M$100M$75M—$117M
Net income$-1M$-15M—$54M$52M$25M—$70M
EPS (diluted)$-0.03$-0.30—$1.10$1.06$0.50—$1.33

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$192M$192M$214M$207M$183M$229M$195M$210M
Inventory$346M$360M$299M$303M$280M$290M$279M$336M
Total current assets$1.53B$1.49B$1.45B$1.53B$1.47B$1.51B$1.40B$1.49B
Total assets$7.53B$7.73B$7.14B$7.51B$7.56B$7.58B$7.53B$8.00B
Long-term debt————————
Total liabilities$4.64B$4.74B$3.92B$4.06B$4.16B$4.34B$4.02B$4.18B
Total equity$2.84B$2.95B$3.16B$3.41B$3.36B$3.20B$3.46B$3.79B

Implied volatility — last 90 days

40%48%57%65%73% Jun 07 — IV 60% · EM ±8.2%Jun 08 — IV 60% · EM ±7.9%Jun 09 — IV 56% · EM ±7.0%Jun 10 — IV 56% · EM ±6.6%Jun 11 — IV 58% · EM ±6.4%Jun 12 — IV 56% · EM ±5.7%Jun 15 — IV 61% · EM ±4.4%Jun 16 — IV 62% · EM ±3.7%Jun 17 — IV 74% · EM ±3.1%Jun 19 — IV 50% · EM ±11.0%Jun 22 — IV 52% · EM ±10.8%Jun 23 — IV 49% · EM ±10.0%Jun 24 — IV 51% · EM ±10.2%Jun 25 — IV 51% · EM ±9.9%Jun 26 — IV 46% · EM ±8.9%Jun 29 — IV 49% · EM ±8.7%Jun 30 — IV 48% · EM ±8.2%Jul 01 — IV 45% · EM ±7.6%Jul 02 — IV 44% · EM ±7.2%Jul 03 — IV 46% · EM ±7.2%Jul 06 — IV 48% · EM ±6.7%Jul 07 — IV 50% · EM ±6.6%Jul 08 — IV 52% · EM ±6.5%Jul 09 — IV 48% · EM ±5.6%Jul 10 — IV 49% · EM ±5.4%Jul 13 — IV 58% · EM ±4.8%Jul 14 — IV 57% · EM ±4.1%Jul 15 — IV 51% · EM ±3.0%Jul 16 — IV 58% · EM ±2.4%Jul 20 — IV 60% · EM ±14.2%Jul 21 — IV 62% · EM ±14.3%Jul 22 — IV 61% · EM ±14.0%Jul 23 — IV 62% · EM ±14.0%Jul 24 — IV 64% · EM ±14.1%Jul 27 — IV 66% · EM ±13.7%Jul 28 — IV 66% · EM ±13.4%Jul 29 — IV 66% · EM ±13.2%Jul 30 — IV 64% · EM ±12.6%Jul 31 — IV 66% · EM ±12.6%Aug 03 — IV 73% · EM ±12.9%Aug 04 — IV 74% · EM ±12.7%Aug 05 — IV 53% · EM ±8.9%Aug 06 — IV 49% · EM ±7.9%Aug 07 — IV 46% · EM ±7.3%Aug 10 — IV 46% · EM ±6.4%Aug 11 — IV 48% · EM ±6.3%Aug 12 — IV 47% · EM ±5.9%Aug 13 — IV 46% · EM ±5.5%Aug 14 — IV 43% · EM ±4.7%Aug 17 — IV 50% · EM ±4.2%Aug 18 — IV 48% · EM ±3.5%Aug 19 — IV 53% · EM ±3.1%Aug 20 — IV 64% · EM ±2.7%Aug 24 — IV 44% · EM ±9.2%Aug 25 — IV 40% · EM ±8.3%Aug 26 — IV 42% · EM ±8.4%Aug 27 — IV 43% · EM ±8.3%Aug 28 — IV 42% · EM ±8.0%Aug 31 — IV 41% · EM ±7.3%Sep 01 — IV 45% · EM ±7.7%Sep 02 — IV 44% · EM ±7.3%Sep 03 — IV 42% · EM ±6.8%Sep 04 — IV 43% · EM ±6.7%Sep 07 — IV 48% · EM ±6.7%Sep 08 — IV 46% · EM ±6.0%Sep 09 — IV 45% · EM ±5.7%Sep 10 — IV 47% · EM ±5.6%Sep 11 — IV 43% · EM ±4.7%Sep 14 — IV 53% · EM ±4.4%Sep 15 — IV 51% · EM ±3.7%Sep 16 — IV 72% · EM ±4.3%Sep 17 — IV 67% · EM ±2.8%Sep 21 — IV 48% · EM ±10.1%Sep 22 — IV 48% · EM ±9.8%Sep 23 — IV 48% · EM ±9.6%Sep 24 — IV 45% · EM ±8.8%Sep 25 — IV 44% · EM ±8.4%Sep 28 — IV 44% · EM ±7.9%Sep 29 — IV 43% · EM ±7.4%Sep 30 — IV 43% · EM ±7.2%Oct 01 — IV 42% · EM ±6.8%Oct 02 — IV 43% · EM ±6.7%Oct 06 — IV 48% · EM ±6.3%Oct 07 — IV 48% · EM ±6.0%Oct 08 — IV 46% · EM ±5.5%

Sector peers

ICLR
ICON plc
$12.6B $185.43+6.5%
MEDP
Medpace Holdings, Inc.
$16.9B $653.96+5.1%
INCY
Incyte Corporation
$23.0B $116.93+0.3%
ABSI
Absci Corporation
$1.8B $9.37+3.3%
OABI
OmniAb, Inc.
$663M $4.78-3.6%
NRC
NRC Health
$447M $21.38+3.3%

CRL earnings FAQ

When is CRL's next earnings date?

Charles River Laboratories International, Inc. is expected to report on November 4, 2026.

What is CRL's expected move for earnings?

Options currently price a move of about ±5.5%, or $18.58 per share either way from $339.66.

How does CRL stock usually react to earnings?

Across the last 6 reports the average next-day move was ±7.7%, up 2 times and down 4 times.

What EPS are analysts expecting from Charles River Laboratories International, Inc.?

The consensus estimate is $2.97 per share, versus $2.43 a year ago.

What is CRL's implied volatility?

CRL's at-the-money implied volatility is about 46% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in